FDA approves first-in-class drug for polycythemia vera
The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals' Mimrylo (rusfertide) as a new treatment for adults ...
Top US doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion
Leading U.S. medical groups are urging people to get updated flu and COVID-19 vaccinations this fall, banding together ...
FDA Approves Updated COVID Vaccines—Here’s What To Know
Updated COVID vaccines are necessary, just as flu vaccines are updated because immunity wanes with time, even among those ...
Clinical Advisor
FDA Approves Updated 2026-2027 COVID-19 Vaccines
FDA approves updated 2026-2027 COVID-19 vaccine formulations targeting the XFG variant for older adults and high-risk individuals.
allsci
FDA approves Takeda's Mimrylo as first hepcidin mimetic for polycythemia vera
FDA approves Mimrylo (rusfertide), the first hepcidin mimetic for polycythemia vera. Takeda's breakthrough treatment offers ...
CURE
Karyopharm Seeks FDA Approval for XPOVIO Plus Ruxolitinib in Myelofibrosis
Karyopharm Therapeutics announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
Healio
Besremi grabs FDA’s first approval in almost 30 years for essential thrombocythemia
The FDA has approved the first treatment for essential thrombocythemia in nearly 30 years, according to a PharmaEssentia ...
Oncology Nursing News
FDA Approves Rusfertide, First-in-Class Hepcidin Mimetic for Polycythemia Vera
FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in ...
FDA approves Protagonist and Takeda’s drug for rare blood cancer
Mimrylo was cleared to treat polycythemia vera, a chronic blood cancer in which overproduction of red blood cells thickens a ...
pharma.economictimes.indiatimes
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Bengaluru: The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, the health regulator said ...